Chipscreen Biosciences released its 2026 interim report, with net profit attributable to the parent company of 71.3806 million yuan. Total operating revenue was 543 million yuan, and net cash inflow from operating activities was 89.3651 million yuan. The latest asset-liability ratio was 44.56 percent, up 0.97 percentage points from the previous quarter. Gross margin was 86.33 percent, down 0.45 percentage points from the same period last year. Return on equity was 2.80 percent. Diluted earnings per share were 0.16 yuan, total asset turnover was 0.13 times, and inventory turnover was 1.20 times. The number of shareholders was 25,600, and the top ten shareholders held 115 million shares, accounting for 25.96 percent of total share capital.
Shenzhen Chipscreen Biosciences CoCompany released interim report with net profit of 71.38 million yuan, indicating positive financial performance.